Medico Intercontinental Ltd
Incorporated in 1914, Medico Intercontinental
Ltd is engaged in trading of Pharmaceutical products[1]
- Market Cap ₹ 25.9 Cr.
- Current Price ₹ 25.9
- High / Low ₹ 43.0 / 20.6
- Stock P/E
- Book Value ₹ 46.9
- Dividend Yield 0.00 %
- ROCE -1.43 %
- ROE -6.70 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.55 times its book value
- Company's working capital requirements have reduced from 122 days to 76.2 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 3.81% over past five years.
- Company has a low return on equity of 4.23% over last 3 years.
- Earnings include an other income of Rs.1.27 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10 | 82 | 70 | 74 | 76 | 71 | 96 | 84 | |
| 0 | 9 | 78 | 65 | 69 | 71 | 66 | 88 | 81 | |
| Operating Profit | -0 | 1 | 4 | 5 | 5 | 5 | 6 | 8 | 3 |
| OPM % | 7% | 5% | 7% | 7% | 7% | 8% | 9% | 4% | |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 8 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 |
| Profit before tax | 0 | 1 | 3 | 4 | 4 | 5 | 5 | 7 | -9 |
| Tax % | 40% | 27% | 26% | 27% | 27% | 27% | 27% | 28% | 19% |
| 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | -11 | |
| EPS in Rs | 0.09 | 2.28 | 7.26 | 7.94 | 9.54 | 3.61 | 3.95 | 5.06 | -3.20 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 3% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 3% |
| TTM: | -12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -163% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -10% |
| 3 Years: | -30% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 4% |
| Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 10 |
| Reserves | 0 | 1 | 3 | 6 | 9 | 31 | 35 | 39 | 37 |
| 0 | 0 | 14 | 9 | 9 | 5 | 5 | 17 | 67 | |
| 1 | 5 | 16 | 12 | 11 | 13 | 6 | 10 | 3 | |
| Total Liabilities | 4 | 9 | 36 | 31 | 32 | 59 | 56 | 76 | 117 |
| 0 | 0 | 2 | 2 | 2 | 3 | 4 | 9 | 51 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| 4 | 9 | 34 | 28 | 30 | 56 | 53 | 67 | 64 | |
| Total Assets | 4 | 9 | 36 | 31 | 32 | 59 | 56 | 76 | 117 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | -14 | 6 | 4 | -10 | 6 | -7 | 17 | |
| 0 | 0 | 0 | -1 | -1 | -5 | -9 | -2 | 2 | |
| 0 | 0 | 13 | -5 | -1 | 20 | -0 | 9 | -16 | |
| Net Cash Flow | 0 | 1 | -0 | -0 | 1 | 5 | -3 | -1 | 4 |
| Free Cash Flow | 0 | 1 | -14 | 5 | 4 | -11 | 4 | -9 | 12 |
| CFO/OP | -6% | 171% | -200% | 138% | 100% | -167% | 118% | -63% | 635% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 237 | 101 | 94 | 84 | 157 | 119 | 125 | 119 | |
| Inventory Days | 0 | 26 | 46 | 58 | 47 | 52 | 69 | 45 | 87 |
| Days Payable | 201 | 74 | 67 | 50 | 67 | 30 | 37 | 82 | |
| Cash Conversion Cycle | 62 | 74 | 85 | 81 | 143 | 158 | 134 | 124 | |
| Working Capital Days | 78 | 74 | 68 | 66 | 132 | 134 | 156 | 76 | |
| ROCE % | 28% | 36% | 25% | 25% | 17% | 12% | 14% | -1% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Count ・Standalone data |
|
|||||||||
| Number of Wholly Owned Subsidiaries Count ・Standalone data |
||||||||||
| Debtors Turnover Ratio Times ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 23 May
-
Announcement under Regulation 30 (LODR)-Meeting Updates
22 May - Board approved re-appointment of M/s. MJV & Co as internal auditor for FY 2026-27.
- Results - Financial Year Ended March 31, 2026. 22 May
-
Board Meeting Outcome for Outcome Of Board Meeting Dated May 22, 2026
22 May - Board approved FY26 audited standalone and consolidated results; internal auditor reappointed on May 22, 2026.
-
Board Meeting Intimation for Board Meeting In Compliance Of Regulation 29, 30 And 33 Of The SEBI (LODR) Regulations, 2015.
14 May - Board meeting on 22 May 2026 to approve audited FY26 standalone and consolidated results.
Business Overview:[1][2]
MIL (Formerly M/S. Intercontinental Leasing
& Finance Company Limited) was in the textile business. Currently, it trades pharmaceutical products related to Gastro, Uro, Nutrition, Cosmetology, Health Devices, Hospital,
etc.